Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gut-directed NLRP3 antagonist (IFM Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A preclinical-stage, gut-directed small molecule NLRP3 antagonist developed by IFM Therapeutics (through its subsidiary IFM Tre) and acquired by Novartis. This compound is specifically designed to target the NLRP3 (NOD-, LRR- and pyrin domain-containing 3) inflammasome locally within the gastrointestinal tract while maintaining low systemic penetration. By selectively inhibiting NLRP3 activity in the gut, the drug aims to reduce the chronic intestinal inflammation characteristic of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, while minimizing potential systemic side effects. The program was part of a 2019 acquisition by Novartis to expand its portfolio of innate immune system modulators.
- Other names
- IFM Tre gut-directed NLRP3 programNovartis gut-directed NLRP3 antagonist
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on gut-directed NLRP3 antagonist (IFM Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gut-directed NLRP3 antagonist (IFM Therapeutics).